Foxf2表达与乳腺癌转移及预后的关系

Clinical Significance of Foxf2 mRNA Expression in Primary Breast Cancer

目的:前期研究发现叉头框(forkhead box,Fox)转录因子Foxf2 mRNA在乳腺淋巴结转移癌中的表达较对应的原发癌下调,是潜在的乳腺癌转移相关基因。本研究通过大样本临床病例检测(分析),阐明乳腺原发癌组织中Foxf2 mRNA水平与临床病理因素的关系,评估其对预测患者预后的临床价值。方法:采用实时定量PCR方法检测233例乳腺原发癌组织中Foxf2 mRNA表达水平;x^2检验比较组间差异;Kaplan-Meier法绘制生存曲线;Log-rank时序检验比较组间生存期的差异。结果:Foxf2 mRNA低表达率在乳腺癌临床Ⅰ～Ⅱ期低于Ⅲ期组(P=0.003),ER阳性组低于ER阴性组(P=0.014),随着阳性淋巴结数的增加,Foxf2 mRNA低表达率逐渐升高(P=0.041),Foxf2 mRNA低水平组患者5年无病生存率低于高水平组(P=0.001)。结论:Foxf2 mRNA低表达与肿瘤进展和患者预后不良相关,Foxf2 mRNA水平是潜在的乳腺癌患者预后分子标志物。

Objective： To clarify the relationship between Foxf2 mRNA level and clinicopathologic factors in breast cancer, and to evaluate its clinical value in predicting the prognosis of breast cancer patients based on a large-sample data. Methods： Real-time reverse transcription-polymerase chain reaction （RT-PCR） was used to detect the mRNA expression level of Foxf2 in primary breast carcinoma of 233 cases which were followed up for more than 3 years. Chi square test was used to compare the differences between/among groups. Survival analysis was carried out using Kaplan-Meier analysis. Log-rank test was used to compare the differences in survival. Results： The expression of Foxf2 mRNA in stage Ⅲ breast cancer was lower than that in stage Ⅰ-Ⅱbreast cancer （P=0.003）. The expression of Foxf2 mRNA in ER-positive breast cancer was lower than that in ER-negative breast cancer （P=0.014）. The expression of Foxf2 mRNA decreased as the number of positive lymph nodes increased （P=0.041）. Disease-free survival of patients with low Foxf2 mRNA expression was lower than those with high Foxf2 mRNA expression （P=0.008）. Conclusion： Low Foxf2 mRNA expression is associated with the development of breast cancer and poor prognosis and can be a potential molecular marker for predicting the prognosis of breast cancer patients.